万孚生物
(300482)
| 流通市值：102.31亿 | | | 总市值：114.43亿 |
| 流通股本：4.30亿 | | | 总股本：4.81亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,181,361,474.64 | 1,575,250,376.82 | 861,092,255.54 | 2,764,914,157.4 |
| 营业收入 | 2,181,361,474.64 | 1,575,250,376.82 | 861,092,255.54 | 2,764,914,157.4 |
| 二、营业总成本 | 1,715,728,355.95 | 1,184,260,271.92 | 609,782,073.05 | 2,294,651,409.08 |
| 营业成本 | 797,669,919.04 | 561,696,946.09 | 290,147,748.24 | 1,033,770,911.55 |
| 税金及附加 | 7,250,386.23 | 5,168,221.37 | 3,035,065.86 | 12,169,762.61 |
| 销售费用 | 472,005,966.72 | 318,499,085.16 | 159,814,237.68 | 649,987,779.66 |
| 管理费用 | 153,220,061.93 | 107,384,846.46 | 58,488,722.9 | 227,126,561.28 |
| 研发费用 | 271,181,881.59 | 197,310,702.68 | 105,547,760.15 | 378,001,427.16 |
| 财务费用 | 14,400,140.44 | -5,799,529.84 | -7,251,461.78 | -6,405,033.18 |
| 其中:利息费用 | 21,634,826.15 | 15,086,854.98 | 7,144,336.06 | 29,934,757.58 |
| 其中:利息收入 | 16,320,029.41 | 13,177,444.85 | 5,273,629.58 | 27,612,652.78 |
| 加:公允价值变动收益 | 24,424,625.34 | 15,572,505.9 | 867,577.36 | 14,798,910.67 |
| 加:投资收益 | 1,964,002.7 | -1,211,510.64 | 2,955,606.08 | 31,099,528.72 |
| 资产处置收益 | 736,983.24 | - | - | 80,136.83 |
| 资产减值损失(新) | - | - | - | -11,521,801.91 |
| 信用减值损失(新) | -18,095,942.9 | -15,273,933.05 | -8,464,136.88 | -1,499,456.3 |
| 其他收益 | 23,445,130.67 | 17,143,589.22 | 5,603,512.83 | 45,918,052.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 498,107,917.74 | 407,220,756.33 | 252,272,741.88 | 549,138,118.89 |
| 加:营业外收入 | 1,072,523.02 | 705,826.29 | 228,831.68 | 3,546,505.31 |
| 减:营业外支出 | 6,344,520.16 | 2,580,756.36 | 897,895.03 | 11,921,965.64 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 492,835,920.6 | 405,345,826.26 | 251,603,678.53 | 540,762,658.56 |
| 减:所得税费用 | 53,019,650 | 47,031,076.2 | 31,160,058.03 | 53,334,297.2 |
| 六、净利润 | 439,816,270.6 | 358,314,750.06 | 220,443,620.5 | 487,428,361.36 |
| 持续经营净利润 | 439,816,270.6 | 358,314,750.06 | 220,443,620.5 | 491,006,240.13 |
| 终止经营净利润 | - | - | - | -3,577,878.77 |
| 归属于母公司股东的净利润 | 435,935,866.11 | 355,800,226.55 | 218,334,248.48 | 487,624,779.55 |
| 少数股东损益 | 3,880,404.49 | 2,514,523.51 | 2,109,372.02 | -196,418.19 |
| (一)基本每股收益 | 0.94 | 0.78 | 0.49 | 1.1 |
| (二)稀释每股收益 | 0.94 | 0.78 | 0.49 | 1.1 |
| 八、其他综合收益 | -222,870.57 | 736,513.98 | 413,477.28 | -109,988,273.54 |
| 归属于母公司股东的其他综合收益 | -222,870.57 | 736,513.98 | 413,477.28 | -109,988,273.54 |
| 九、综合收益总额 | 439,593,400.03 | 359,051,264.04 | 220,857,097.78 | 377,440,087.82 |
| 归属于母公司股东的综合收益总额 | 435,712,995.54 | 356,536,740.53 | 218,747,725.76 | 377,636,506.01 |
| 归属于少数股东的综合收益总额 | 3,880,404.49 | 2,514,523.51 | 2,109,372.02 | -196,418.19 |
| 公告日期 | 2024-10-25 | 2024-08-14 | 2024-04-22 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |